Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Histone deacetylase inhibitors (HDACi) are anticancer agents that induce hyperacetylation of histones, resulting in chromatin remodeling and transcriptional changes. In addition, nonhistone proteins, such as the chaperone protein Hsp90, are functionally regulated through hyperacetylation mediated by HDACis. Histone acetylation is thought to be primarily regulated by HDACs 1, 2, and 3, whereas the acetylation of Hsp90 has been proposed to be specifically regulated through HDAC6. We compared the molecular and biologic effects induced by an HDACi with broad HDAC specificity (vorinostat) with agents that predominantly inhibited selected class I HDACs (MRLB-223 and romidepsin). MRLB-223, a potent inhibitor of HDACs 1 and 2, killed tumor cells using the same apoptotic pathways as the HDAC 1, 2, 3, 6, and 8 inhibitor vorinostat. However, vorinostat induced histone hyperacetylation and killed tumor cells more rapidly than MRLB-223 and had greater therapeutic efficacy in vivo. FDCP-1 cells dependent on the Hsp90 client protein Bcr-Abl for survival, were killed by all HDACis tested, concomitant with caspase-dependent degradation of Bcr-Abl. These studies provide evidence that inhibition of HDAC6 and degradation of Bcr-Abl following hyperacetylation of Hsp90 is likely not a major mechanism of action of HDACis as had been previously posited. Mol Cancer Ther; 12(12); 2709–21. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 10×
“It has been proposed that inhibition of HDAC6 resulting in hyperacetylation of Hsp90 and release and degradation of client oncoproteins such as Bcr-Abl is important for the antitumor activities of HDACis (3, 10).”
BackgroundResultInfluentialSelf-citationHSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 2×
“Consistent with the HDAC-specific inhibitory properties of the two agents, both vorinostat and MRLB-223 induced histone hyperacetylation; however, only vorinostat induced acetylation of a-tubulin, a function known to be regulated by HDAC6 (37).”
BackgroundAcetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 2×
“In addition to histones, the function, localization, or stability of a number of nonhistone proteins can be regulated by acetylation (5) and, thus, the combined effects of HDACi on histone and nonhistone proteinsmay be important for the therapeutic activities of these compounds (14).”
BackgroundHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · cited 1×
“A large number HDAC inhibitors (HDACi) have been developed that can suppress HDAC enzymatic activity and mediate protein acetylation (1, 2).”
BackgroundSelf-citationHDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · cited 2×
“Hsp90 is deacetylated by HDAC6 (24), and HDACis capable of inhibiting HDAC6 induce the hyperacetylation of Hsp90, resulting in proteosomal degradation of Hsp90 client proteins ErbB1,”
BackgroundBali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755 · cited 2×
“In addition to the lack of antitumor effects of the HDAC6 inhibitor tubacin, siRNA-mediated knockdown of HDAC6 resulted in hyperacetylation and loss of chaperone function of Hsp90, but had little or no effect on tumor cell growth and survival (29) Moreover, a significant number of HDACis that are potent mediators of t…”
BackgroundHDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · cited 1×
“serves as a surrogate readout for HDAC6 activity in cellbased systems (37, 38).”
BackgroundChemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575 · cited 1×
“However, although there have been some reports of single HDAC inhibition affecting tumor cell growth as transient knockdown of HDAC1 or HDAC3 suppressed HeLa cell proliferation (20), another group showed that transient knockdown ofHDAC1, 2, or 3decreased the rate of proliferation of colon carcinoma cell lines (21).”
Background
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Self-citationHDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Shirasaki, R., Matthews, G. M., Gandolfi, S., de Matos Simoes, R., Buckley, D. L., Raja Vora, J., Sievers, Q. L., Brüggenthies, J. B., Dashevsky, O., Poarch, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108532 · Cited by 123
Self-citationWang, Y., Stowe, R. L., Pinello, C. E., Tian, G., Madoux, F., Li, D., Zhao, L. Y., Li, J.-L., Wang, Y., Wang, Y., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.015 · Cited by 122
“The aminobenzamide class of HDACi is selective to class I HDACs (HDACs 1–3) and displays unique slow-on/slow-off HDAC-binding kinetics (Beconi et al., 2012; Chou et al., 2008; Lauffer et al., 2013; Newbold et al., 2013).”
Deng, S., Hu, Q., Zhang, H., Yang, F., Peng, C., & Huang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1068 · Cited by 116
Metadata
- Authors
- Newbold, A., Matthews, G. M., Bots, M., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C., Bolden, J. E., Christiansen, A. J., Dickins, R. A., Miccolo, C., Chiocca, S., Kral, A. M., Ozerova, N. D., Miller, T. A., Methot, J. L., Richon, V. M., Secrist, J. P., Minucci, S., & Johnstone, R. W.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-12-01
- Volume
- 12
- Issue
- 12
- Pages
- 2709-2721
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2059540635
- Cited by
- 46
- References
- 11
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0626
- The paper
- Newbold, A., Matthews, G. M., Bots, M., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C., Bolden, J. E., Christiansen, A. J., Dickins, R. A., Miccolo, C., Chiocca, S., Kral, A. M., Ozerova, N. D., Miller, T. A., Methot, J. L., Richon, V. M., Secrist, J. P., Minucci, S., & Johnstone, R. W. (2013). Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0626
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.